THE DIFFICULTIES IN THE DIAGNOSIS OF PULMONARY HYPERTENSION ASSOCIATED WITH CHRONIC LUNG DISEASE.

chronic lung disease- chronic obstructive pulmonary disease- idiopathic pulmonary fibrosis - interstitial lung disease- pulmonary hypertension-

Journal

Wiadomosci lekarskie (Warsaw, Poland : 1960)
ISSN: 0043-5147
Titre abrégé: Wiad Lek
Pays: Poland
ID NLM: 9705467

Informations de publication

Date de publication:
2020
Historique:
entrez: 25 10 2020
pubmed: 26 10 2020
medline: 28 10 2020
Statut: ppublish

Résumé

Introduction: Chronic lung disease (WHO group 3) is the second leading cause of pulmonary hypertension (PH). In turn, the development of PH influences the course of lung disease, worsening the clinical symptoms and prognosis. The aim: To analyse the difficulties in the diagnosis of pulmonary hypertension due to chronic lung disease. Review and Discussion: According to recent literature, PH in the course of lung diseases develops as a result of both "parenchymal" and vascular pathology in patients with a genetic predisposition. Prolonged infection (especially viral) may be an additional promoting factor. Elevation of pulmonary arterial pressure (PAP) is usually moderate and correlates with severity of lung disease. In a small minority, PAP may reach that seen in WHO group 1 pulmonary arterial hypertension (PAH). Conclusions: Echocardiography and right heart catheterization are the principal tools for the diagnosis of PH in chronic lung diseases. Unfortunately, current medications for treating PAH have not shown benefit in controlled trials of group 3 PH, hence their routine use is not recommended. Patients with severe group 3 PH should be considered for referral to expert centres or entry into clinical trials.

Identifiants

pubmed: 33099529

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1853-1860

Auteurs

Sylwia Łukasik (S)

DEPARTMENT OF CARDIOLOGY, MEDICAL UNIVERSITY OF LUBLIN, LUBLIN, POLAND.

Dariusz Łukasik (D)

DEPARTMENT OF CARDIOLOGY, MEDICAL UNIVERSITY OF LUBLIN, LUBLIN, POLAND.

Michał Tomaszewski (M)

DEPARTMENT OF CARDIOLOGY, MEDICAL UNIVERSITY OF LUBLIN, LUBLIN, POLAND.

Weronika Topyła (W)

DEPARTMENT OF CARDIOLOGY, MEDICAL UNIVERSITY OF LUBLIN, LUBLIN, POLAND.

Agnieszka Wojtowska (A)

DEPARTMENT OF CARDIOLOGY, MEDICAL UNIVERSITY OF LUBLIN, LUBLIN, POLAND.

Aleksandra Szopa (A)

DEPARTMENT OF APPLIED AND SOCIAL PHARMACY, LABORATORY OF PRECLINICAL TESTING, MEDICAL UNIVERSITY OF LUBLIN, LUBLIN, POLAND.

Andrzej Wysokiński (A)

DEPARTMENT OF CARDIOLOGY, MEDICAL UNIVERSITY OF LUBLIN, LUBLIN, POLAND.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH